Concert must submit toxicology data to the FDA before proceeding with Phase 2 trials.
Is this the report the bulls have been waiting for?
Canaccord is bullish on Edwards Lifescience stock.
These stocks are indicating a change in direction.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.